MIRACLE Medical Technology Act of 2025
Summary
The MIRACLE Medical Technology Act of 2025 (HR661) is an early-stage House bill authorizing HHS to establish a U.S.-Israel healthcare product development collaboration program. It has no funding allocation, was referred to committee in January 2025, and has seen no further action. Market impact is negligible at this stage; any benefit to med-tech companies or CROs requires a future appropriations bill and a long legislative path.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR661 is an unfunded authorizing bill in early committee stage with zero legislative momentum since January 2025.
- 2.No market-observable impact possible until a separate appropriations bill allocates money to the collaboration program.
- 3.Any potential benefit to med-tech and CRO firms is years away and contingent on multiple legislative steps.
Market Implications
No current market implications. This bill is a procedural placeholder with no funding, no hearings, and no timeline. Investors should ignore it until either (a) the bill is marked up in committee or (b) a companion Senate bill emerges. Neither has occurred in 15 months since introduction.
Full Analysis
What happened and its current status: HR661, the MIRACLE Medical Technology Act, was introduced on January 23, 2025, by Representative Vern Buchanan (R-FL-16) with three cosponsors. The bill was referred to the House Committee on Energy and Commerce the same day and has had no subsequent actions — no hearings, markups, or floor votes in over 15 months. It remains in early-stage limbo typical of uncontroversial but unfunded authorizing bills.
The money trail: The bill contains zero appropriated funding. The operative language reads 'Subject to the availability of appropriations,' meaning Congress must pass a separate appropriations bill to fund the collaboration program. Typical U.S.-Israel bilateral health programs (like the U.S.-Israel Binational Industrial R&D Foundation, BIRD) have annual appropriations in the $3-5 million range. Even if this bill passed, the market impact would be marginal for a sector worth hundreds of billions.
Structural winners and losers: The bill's language is broad, covering medical device technology, biological products, digital health, and early-stage clinical trials. Potential long-term beneficiaries include large-cap med-tech companies with R&D exposure to Israel ($ISRG, $MDT), clinical CROs with Israeli operations (, ), and digital health firms. However, without funding, these are speculative connections. The Department of Health and Human Services is the obligated party, not private companies.
Timeline: The legislative path is long. The bill must survive committee markup (not yet scheduled), pass the House, pass the Senate (no companion bill exists), and be signed into law. Then appropriators must fund it. The 119th Congress ends January 2027; this bill has almost no chance of enactment before then without significant committee chair support or addition to a must-pass package.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Authorizes HHS to establish a joint U.S.-Israel program for collaborative development of health care products and services, including medical device technology and early-stage clinical trials.
Who must act
Department of Health and Human Services, in consultation with FDA, CMS, and Commerce.
What happens
The bill does not appropriate funding or mandate specific procurement; it only authorizes a coordination program subject to future appropriations. No direct economic effect on any obligated party until subsequent funding is passed.
Stock impact
ISRG is a leader in robotic-assisted surgery (da Vinci system) with R&D facilities; potential long-term collaboration with Israeli medical device startups could create new technology integration opportunities, but the early-stage and unfunded nature means zero near-term revenue impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Ensuring Patient Access to Critical Breakthrough Products Act
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
FERMI FORWARD DISCOVERY GROUP, LLC: $2.4B Department of Energy Contract
FERMI FORWARD DISCOVERY GROUP, LLC: $2.4B Department of Energy Contract
FERMI FORWARD DISCOVERY GROUP, LLC: $2.4B Department of Energy Contract
HII MISSION TECHNOLOGIES CORP: $579M General Services Administration Contract
VERTEX AEROSPACE LLC: $513M General Services Administration Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Establishing an America First Arms Transfer Strategy
This executive order directs the Secretary of War, along with the Secretaries of State and Commerce, to create an 'America First Arms Transfer Strategy' that prioritizes foreign arms sales to boost U.S. defense industrial base capacity, streamline export processes, and enhance production of key weapons systems. It mandates a sales catalog of prioritized platforms within 120 days, forms a task force to improve coordination, and reforms congressional notification procedures for arms transfers.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →